# Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)

Study · id `cardio:ct-nct01096667` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01096667](<https://clinicaltrials.gov/study/NCT01096667>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01096667

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 194 participants.

## Technical summary

Registry record NCT01096667. Randomized; double masking; primary purpose treatment. Start 2010-05-17 (actual); primary completion 2011-02-09 (actual). Results posted on 2017-12-13.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 194 participants (enrolled count; ClinicalTrials.gov record NCT01096667, source copy `cardio:ctgov-nct01096667-2018-09-13`, retrieved 2026-10-26)
- Started: 2010-05-17 (actual) (ClinicalTrials.gov record NCT01096667, source copy `cardio:ctgov-nct01096667-2018-09-13`, retrieved 2026-10-26)
- Primary completion: 2011-02-09 (actual) (ClinicalTrials.gov record NCT01096667, source copy `cardio:ctgov-nct01096667-2018-09-13`, retrieved 2026-10-26)
- Completion: 2011-02-25 (actual) (ClinicalTrials.gov record NCT01096667, source copy `cardio:ctgov-nct01096667-2018-09-13`, retrieved 2026-10-26)
- Results first posted: 2017-12-13 (ClinicalTrials.gov record NCT01096667, source copy `cardio:ctgov-nct01096667-2018-09-13`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01096667-2018-09-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)
- Condition: Diabetes Mellitus, Type 2
- Condition: Hypertension
- Intervention (Drug): Placebo to Ertuglilflozin 1 or 5 mg
- Intervention (Drug): Ertugliflozin 1 mg
- Intervention (Drug): Ertugliflozin 5 mg
- Intervention (Drug): Ertugliflozin 25 mg
- Intervention (Drug): HCTZ 12.5mg
- Intervention (Drug): Placebo to HCTZ
- Intervention (Drug): Placebo to ertuglilflozin 25 mg
- Lead sponsor: Merck Sharp & Dohme LLC
- Lead sponsor class: INDUSTRY
- Collaborator: Pfizer
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)
- Registry lists this organization as a collaborator: Pfizer (`cardio:org-pfizer`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension (`cardio:pubmed-25951755`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 454573487a61cf1174c7fe17b432990d9b8910f9ec04881a36a1b6afd5b370c0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
